Halaman 4 - Rontgen Dada Dokter Terbaik - TOP-187 dokter

I was born in Adana in 1983. I graduated from Hacettepe University (ing) in 2007 and started to work as an orthopedic assistant at İzmir Atatürk Training and Research Hospital in 2008. I did my master's thesis on the rotator cuff healing of dicholefenac sodium. As a specialist in 2013, I started at Okmeydanı Training and Research Hospital and got my associate professorship there in 2018. In 2017, I worked as a Clinical fellow in the publication of Prof Dr Philip Lobenhoffer for Knee Circumferential Osteotomies, unicondylar and total knee arthroplasty in Germany (Go:h Sports Clinic/Hannover). I started working at Istinye University Hospital in 2019. I am married and have 2 children.

Research Areas: Knee surgery, Shoulder surgery, Ankle surgery, Artoplasty

Basic Areas: Orthopedics and Traumatology,

Awards

(2015), "Derviş Manizade Science Award", "Professional Associations", "Award received from domestic public institutions and organizations in the field", "Turkish Orthopedics and Traumatology Association", Science - Art Awards

(2017), "Tusyad Overseas Traveling Education Scholarship", "Professional Associations", "Award received from domestic public institutions and organizations in the field", "Turkish Sports Injuries Arthroscopy and Knee Surgery Association", Other

(2016), "Best Experimental Study Poster Award Winner", "Professional Associations", "Award from domestic public institutions and organizations", "Bone Joint Surgery Association", Other

(2015), "25th National Turkish Orthopedics and Traumatology Congress, first place in the poster category", "Professional Associations", "Award received from domestic public institutions and organizations in the field", "Turkish Association of Orthopedics and Traumatology Association", Work Award
 

Dr. Jirachai Pisutbenya is a spine surgeon. He specializes in endoscopic and minimally invasive spine surgery. He also treats adult spinal deformity and cervical spine disorders.

Accreditations: MD, Faculty of Medicine Ramathibodi Hospital, Mahidol University (2007). Orthopedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University (2014). Spinal Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University (2018).

Dr. Pongtep Na Nakorn is a specialist in sports medicine. He focuses on shoulder and knee arthroscopic surgery.

Accreditations: Doctor of Medicine, Faculty of Medicine, Prince of Songkhla University (2007). Orthopedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University (2016). Sports Medicine, Faculty of Medicine, Thammasat University (2017).

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Dr. Viola Fox adalah Kepala Dokter di Klinik Hematologi, Onkologi, dan Kedokteran Paliatif di BKZ Solingen. Klinik ini merupakan pusat kanker interdisipliner yang telah tersertifikasi. Dr. Fox adalah pakar terkemuka dalam terapi obat untuk penyakit tumor di Jerman dan Eropa. Dia memiliki lebih dari 15 tahun pengalaman di bidang ini.

Dia adalah anggota dari German Society of Oncology and Haemato-oncology (GDHO), German Association of Physicians, dan American Association for Cancer Research. Dr. Fox juga aktif dalam penelitian biologi molekuler. Karyanya mendukung kemajuan dalam pengobatan kanker dan diagnostik molekuler.

Bidang keahliannya meliputi kemoterapi, imunoterapi, terapi target, dan terapi radiasi. Dr. Fox dikenal karena metode-metodenya yang inovatif dan komitmen kuatnya terhadap perawatan pasien. Usahanya telah menghasilkan tingkat pemulihan yang tinggi dan pengakuan dari rekan-rekannya.

Dr. Victor Alexander Krol - Kepala Gastroenterologi, Penyakit Dalam dan Pusat Pengobatan Obesitas di Rumah Sakit Martinus

Dr. Victor Alexander Krol adalah seorang spesialis yang sangat berkualifikasi, memimpin departemen gastroenterologi dan penyakit dalam. Dengan pengalaman bertahun-tahun dan pengetahuan mendalam di bidangnya, Dr. Krol telah membuktikan dirinya sebagai ahli luar biasa, memberikan perawatan komprehensif dan pendekatan individual kepada pasien. Dia secara aktif menggunakan metode terbaru dalam diagnosis dan pengobatan penyakit saluran pencernaan, metabolisme, serta penyakit sistem kardiovaskular dan pernapasan.

Dr. Krol juga merupakan direktur Pusat Pengobatan Obesitas bersertifikat di Rumah Sakit Martinus, yang menyediakan perawatan bedah dan endoskopi untuk obesitas. Pusat ini menggunakan teknologi canggih untuk mendiagnosis dan mengobati obesitas (adiposis), termasuk metode seperti bedah bariatrik, penurunan berat badan endoskopi, dan program khusus untuk pasien dengan berbagai tahapan obesitas. Pusat ini bersertifikat dengan standar tinggi dan memiliki hasil yang sangat baik dalam pengobatan penyakit serius ini.

Departemen Gastroenterologi, yang dipimpin oleh Dr. Krol, mendiagnosis dan mengobati penyakit perut, usus, hati, pankreas, dan kantong empedu. Dokter di departemen ini menggunakan berbagai metode, termasuk prosedur endoskopi, ultrasound, dan teknologi diagnostik modern lainnya.

Departemen Penyakit Dalam mencakup berbagai penyakit, termasuk kardiologi, diabetologi, infektologi, dan terapi penyakit pernapasan serta ginjal. Dr. Krol dan timnya memberikan pendekatan komprehensif untuk pengobatan dengan menggunakan metode pengobatan paling maju.

Berkat profesionalismenya yang tinggi dan pendekatan humanis terhadap setiap pasien, Dr. Krol secara layak mendapatkan penghormatan dari rekan kerja dan pasien.

Pendidikan dan Spesialisasi

• Fakultas Kedokteran Universitas Uludağ
• Fakultas Kedokteran Universitas Selçuk Meram, Departemen Kardiologi – Spesialisasi

Pengalaman

• Cleveland Clinic, Unit Kardiologi Invasif, Ohio, AS
• Fakultas Kedokteran Universitas Akdeniz, Departemen Kardiologi
• Rumah Sakit Yaşam Antalya  

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Dr. Marc Ulrich Becher is an interventional cardiologist and heart failure specialist at Städtisches Klinikum Solingen. He is known for performing advanced procedures such as coronary angiography, radiofrequency ablation with 3D mapping, carotid angioplasty, and stenting.

Dr. Becher’s clinic carries out about 3,000 to 4,000 diagnostic and therapeutic procedures each year. These include complex coronary interventions, catheter-based valve replacements, and structural heart procedures. He is experienced in using advanced imaging techniques like IVUS and OCT for accurate diagnosis and treatment planning.

Dr. Becher is dedicated to providing thorough and compassionate care. He uses modern therapies for both acute and chronic cardiovascular diseases, focusing on patient safety and positive outcomes.

Dr. med. Sven Rogmans is an experienced Orthopaedic and Joint Replacement Surgeon with over 28 years in clinical practice. He treats osteoarthritis using both conservative and surgical methods. He is skilled in minimally invasive hip joint replacement and manages lower limb periprosthetic fractures.

Dr. Rogmans graduated from Ruprecht-Karls-Universität in Heidelberg, Germany. He is known for his advanced arthroscopic surgery for sports injuries. He has published many articles in national and international medical journals, showing his dedication to research and progress in orthopaedics.

1997 - 2002 Universitas Istanbul Fakultas Kedokteran Cerrahpaşa, Departemen Ortopedi dan Traumatologi

1990 - 1996 Universitas Istanbul Fakultas Kedokteran Cerrahpasa

Artikel yang ditulis dan dikontribusikan oleh;

Efikasi klinis dari injeksi plasma kaya platelet peritendinous dalam pengobatan tendinopati: Studi retrospektif Aybars Kıvrak* (a), Mehmet Can Ünlü (a), Esref Terzi (a), Olgar Birsel (b), Doruk Akgun (c), Yusuf Pirincci (d), Gokhan Kaynak(a), Isik Akgun (e) Efek jangka menengah dan panjang dari cincin atap asetabular dan kerangka anti-protrusio Burch-Schneider dalam revisi asetabular pada pasien dengan defisiensi tulang asetabular Korespondensi: Yusuf Pirinççi, Muhammed Taha Demir, Mumammet Salih, Fahri Erdoğan, Nejat Güney

Variabel dimensional dari femur proksimal pada displasia pinggul dewasa perkembangan menunjukkan bahwa desain penyusutan berbentuk persegi panjang mungkin menjadi pilihan optimal untuk pasien dengan pinggul tipe IV Crowe

Spesialisasi

Pemanjangan Kaki 

Bedah Olahraga

Robekan Meniskus

Robekan Ligamen Krusiatum Anterior

Prostesis Lutut

Prostesis Pinggul

Prostesis Bahu

Perbaikan SLAP Bahu

Perpanjangan Tinggi Badan

Bedah Tumor

Bedah Kaki (Hallux Valgus)

Kaki Diabetik

Infeksi Tulang (Osteomielitis)

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Yang Young-Joon, MD, is an orthopedic surgeon and Director of the Joint Center. He treats knee and shoulder disorders, sports injuries, foot and ankle problems, carpal tunnel syndrome, and fractures and other trauma. His practice also includes joint replacement, arthroscopic surgery, pediatric orthopedics, hip disorders, hand and foot microsurgery, hand numbness, diabetic foot, hallux valgus, and gout.

He completed his orthopedic surgery residency at Catholic Central Medical Center and an orthopedic surgery fellowship at St. Paul’s Hospital at Catholic Central Medical Center. He is a regular member of the Korean Arthroscopy, Knee, and Shoulder Societies and serves as Director of the Orthopedic Center at Naeun Hospital.

Education and Specialization

• 1982 - 1987: Ege University Faculty of Medicine
• 1987 - 1993: İzmir Atatürk Training and Research Hospital – Specialization

Experience

• 1993 - 1996: İzmir Atatürk State Hospital – Specialist Doctor
• 1996 - 1998: İnönü University Faculty of Medicine – Assistant Professor
• 1998 - 2001: İnönü University Faculty of Medicine – Associate Professor
• 2001 - 2005: Başkent University Adana Practice and Research Hospital – Associate Professor
• 2006 - 2007: Başkent University Adana Practice and Research Hospital – Professor
• 2007 - 2013: Başkent University Istanbul Practice and Research Hospital – Professor
• 2013 - 2015: Hisar Intercontinental Hospital, Istanbul – Professor
• 2015 - Present: Acıbadem Bakırköy Hospital, Istanbul – Professor

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Personal Information

Name Surname : Serdar TOKER
Place of Birth - Year :    Istanbul - 1972
Academic Title : Assoc. Dr.
Foreign Language : English

Education

Ege University Faculty of Medicine - Graduation
Sisli Etfal Training and Research Hospital - Specialised
Work Experience

1998 - 2003 Sisli Etfal Training and Research Hospital
2003 - 2004 Kars State Hospital
2004 - 2006 Erzurum Regional Training and Research Hospital
2006 - 2009 Dumlupınar University Faculty of Medicine, Department of Orthopaedics and Traumatology 
2009 - 2010 Research Fellow. Colorado University Denver Healt Centre Rocky Mountain Regional Trauma Centre Department of Orthopaedics and Hand Surgery
2010 - 2016 Necmettin Erbakan University Department of Orthopaedics and Traumatology. Head of Hand Surgery Department
Courses - Seminars and Certificates Received

2013 FESSH (Federation of European Societies for Surgery of the Hand) European Diploma
2015 RMCD Microsurgery Course Course Chair
2015 National Turkish Orthopaedics and Traumatology Congress Speaker
2015 RMCD Congress Speaker
2014 National Turkish Orthopaedics and Traumatology Congress Speaker
2013 - 2014 Rıdvan Ege Hand Surgery Course Instructor
2013 RMCD Microsurgery Course Instructor
2013 RMCD Congress Session Chair
2012 Shoulder Elbow Surgery Course Instructor
2012 Subspeciality Diploma in Hand Surgery
2011 RMCD Microsurgery Course
2009 Ankle Arthroscopy Course
2008 Knee Arthroscopy Course
2005 Ilizarov Applications Course

Dr. Wuttichai Sutantavibul is an orthopedic surgeon focused on spine care. He specializes in vertebroplasty and kyphoplasty, percutaneous screw fixation, epidural steroid injection, minimally invasive spinal surgery, and endoscopic spine surgery.

Education and fellowships: 2006: Medical degree, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok. 2015: Residency in orthopedic surgery, Ramathibodi Hospital. 2022: Fellowship in spine surgery, Ramathibodi Hospital. 2023: Fellowship in minimally invasive endoscopic spine surgery, Seoul Sangyero Hospital, South Korea. 2023: Minimally invasive and microendoscopic spine surgery training, Wakayama Medical University, Japan.